Re-structuring lentiviral vectors to express genomic RNA via cap-dependent translation

Bibliographic Details
Title: Re-structuring lentiviral vectors to express genomic RNA via cap-dependent translation
Authors: John R. Counsell, Guillaume De Brabandere, Rajvinder Karda, Marc Moore, Antonio Greco, Alysha Bray, Juan Antinao Diaz, Dany P. Perocheau, Ulrike Mock, Simon N. Waddington
Source: Molecular Therapy: Methods & Clinical Development, Vol 20, Iss , Pp 357-365 (2021)
Publisher Information: Elsevier, 2021.
Publication Year: 2021
Collection: LCC:Genetics
LCC:Cytology
Subject Terms: Genetics, QH426-470, Cytology, QH573-671
More Details: Lentiviral (LV) vectors based on human immunodeficiency virus type I (HIV-1) package two copies of their single-stranded RNA into vector particles. Normally, this RNA genome is reverse transcribed into a double-stranded DNA provirus that integrates into the cell genome, providing permanent gene transfer and long-term expression. Integration-deficient LV vectors have been developed to reduce the frequency of genomic integration and thereby limit their persistence in dividing cells. Here, we describe optimization of a reverse-transcriptase-deficient LV vector, which enables direct translation of LV RNA genomes upon cell entry, for transient expression of vector payloads as mRNA without a DNA intermediate. We have engineered a novel LV genome arrangement in which HIV-1 sequences are removed from the 5′ end, to enable ribosomal entry from the 5′ 7-methylguanylate cap for efficient translation of the vector payload. We have shown that this LV-mediated mRNA delivery platform provides transient transgene expression in vitro and in vivo. This has a potential application in gene and cell therapy scenarios requiring temporary payload expression in cells and tissues that can be targeted with pseudotyped LV vectors.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2329-0501
Relation: http://www.sciencedirect.com/science/article/pii/S2329050120302539; https://doaj.org/toc/2329-0501
DOI: 10.1016/j.omtm.2020.12.005
Access URL: https://doaj.org/article/91dfe80765324ae6b172bc6c3bfd05e5
Accession Number: edsdoj.91dfe80765324ae6b172bc6c3bfd05e5
Database: Directory of Open Access Journals
More Details
ISSN:23290501
DOI:10.1016/j.omtm.2020.12.005
Published in:Molecular Therapy: Methods & Clinical Development
Language:English